Intrapleural therapy with ok - 432 and hcpt in malignant pleural effusion 局部灌注沙培林和羟基喜树碱治疗恶性胸腔积液
Intrapleural instillation with ok - 432 and hydroxycamptothecin for malignant pleural effusion 治疗恶性胸腔积液的对照观察
We conducted a trial to clarify the therapeutic role of intrapleural streptokinase 我们进行了一项试验,以阐明胸膜腔内应用链激酶的治疗作用。
Intrapleural instillation of cisplatin and interleukin - 2 in the treatment for malignant pleural effusion 顺铂联合白细胞介素2腔内治疗恶性胸腔积液
Intrapleural streptokinase for pleural infection a step forward in managing pleural effusions 胸膜腔内滴注链激酶治疗胸膜腔感染这是胸膜腔积液治疗的进步吗
Background intrapleural fibrinolytic agents are used in the drainage of infected pleural - fluid collections 背景在感染性胸腔积液引流中,应用了胸膜腔内溶纤维蛋白制剂。
Clinical observation of intrapleural injection of urokinase for patients with encapsulated tuberculous pleural effusion 胸腔内注入尿激酶辅助治疗结核性纤维化性胸腔积液的临床观察
Clinical observation on malignant pleural effusion treated by intrapleural perfusion of staphylococcal entero toxin combined with hydroxycamptothecin 香菇多糖联合羟基喜树碱治疗癌性胸腔积液临床观察
Conclusions the intrapleural administration of streptokinase does not improve mortality , the rate of surgery , or the length of the hospital stay among patients with pleural infection 结论在胸膜感染的病人中,链激酶胸膜腔内给药不能改善死亡率、手术率或住院时间的长短。